Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4
Human cytochrome P450 CYP3A4 is involved in the processing of more than 35% of current pharmaceuticals and therefore is responsible for multiple drug-drug interactions (DDI). In order to develop a method for the detection and prediction of the possible involvement of new drug candidates in CYP3A4-me...
Main Authors: | Ilia G. Denisov, Yelena V. Grinkova, Mark A. McLean, Tyler Camp, Stephen G. Sligar |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/12/6/853 |
Similar Items
-
A Conserved Allosteric Site on Drug-Metabolizing CYPs: A Systematic Computational Assessment
by: André Fischer, et al.
Published: (2021-12-01) -
Sex and Age Influence on Association of <i>CYP450</i> Polymorphism with Midazolam Levels in Critically Ill Children
by: Carmen Flores-Pérez, et al.
Published: (2022-11-01) -
Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes
by: Florian Klomp, et al.
Published: (2020-12-01) -
Impact of Pomegranate Juice on the Pharmacokinetics of CYP3A4- and CYP2C9-Mediated Drugs Metabolism: A Preclinical and Clinical Review
by: Kenza Mansoor, et al.
Published: (2023-02-01) -
Assessment of Substrate Status of Drugs Metabolized by Polymorphic Cytochrome P450 (CYP) 2 Enzymes: An Analysis of a Large-Scale Dataset
by: Jakob Sommer, et al.
Published: (2024-01-01)